Benzinga | Sep 7, 2021 06:29AM EDT

Centogene Q2 Revenues 51.9M, Up 434% YoY; Commercial OVID-19 Testing Revenues 42.3M, Up From 2.1M YoY

Revenues of ?51.9 million in Q2 2021, a 434% increase compared to ?9.7 millionin Q2 2020; Revenues from the Company?s Pharma and Diagnostics segments (?CoreBusiness?) increased 25%

? Clinical Diagnostics revenues (excl. COVID) of ?6.7 million, an increase of 82% compared to ?3.6 million in Q2 2020

? Pharma revenues of ?2.8 million in Q2 2021, down from ?3.9 million in Q2 2020, with further revenues weighted towards the end of 2021

? Commercial COVID-19 testing revenues of ?42.3 million in Q2 2021, up from ?2.1 million in Q2 2020

Positive total segment adjusted EBITDA of ?7.5 million compared to ?1.0 ? million in Q2 2020 from our Pharma, Diagnostics, and COVID-19 testing segments

? Cash and cash equivalents of ?34.8 million as of June 30, 2021, compared to ?45.2 million for the period ending March 31, 2021